NextFin News - Novo Nordisk is shifting its strategy from organic dominance to aggressive acquisition as the Danish pharmaceutical giant attempts to defend its territory in the increasingly crowded obesity market. Speaking in an interview with CNBC on Wednesday, Mike Doustdar, Chief Executive Officer of Novo Nordisk, stated that the company is now more active than ever in seeking out deals to bolster its drug pipeline. The admission marks a pivot for the maker of Ozempic and Wegovy, which has historically relied on its internal GLP-1 expertise but now faces a formidable challenge from Eli Lilly and a wave of next-generation competitors.
The urgency behind Doustdar’s comments follows a period of uncharacteristic volatility for the company. While Novo Nordisk raised its full-year profit guidance on Wednesday after its Wegovy pill performed better than expected in the first quarter, the broader narrative has been clouded by clinical setbacks. In February, the company’s most advanced next-generation candidate, CagriSema, failed to demonstrate non-inferiority to Eli Lilly’s tirzepatide in a head-to-head trial. This failure has weighed heavily on the stock; despite a recent recovery to approximately $48.48 per share, the company’s market capitalization of roughly $210 billion remains significantly below its peaks from the previous year.
Doustdar argued that to help hundreds of millions of patients, the company requires the broadest pipeline in the world, not just the best. He dismissed analyst skepticism regarding the robustness of Novo’s future offerings, pointing to the accelerated development of zenagamtide and the upcoming regulatory decision for CagriSema expected by late 2026. However, the CEO’s "wait and see" message to investors highlights a growing gap between the company’s internal optimism and the market’s demand for tangible data. Eli Lilly has already overtaken Novo in market share for weekly GLP-1 injections, forcing the Danish firm to fight for leadership in the emerging category of weight-loss pills.
The shift toward business development and acquisitions suggests that Novo Nordisk is no longer confident that its internal labs can outpace the industry alone. By seeking complementary assets, the company is effectively admitting that the "moat" provided by its early entry into the GLP-1 space is thinning. Analysts have noted that while Novo’s trailing price-to-earnings ratio of 11.6 times looks historically cheap compared to its five-year median of 35.4, this valuation reflects a "pipeline risk premium" that only successful deal-making or clinical breakthroughs can erase.
The competitive landscape is further complicated by the rise of "copycat" versions of GLP-1 drugs. Although Novo shares saw a brief reprieve earlier this year after U.S. government threats to crack down on knockoffs, the long-term pressure on pricing and exclusivity remains a central concern for the board. Doustdar’s pivot toward a more active M&A stance may be the only viable path to maintaining the company’s premium status in a sector where the first-mover advantage is rapidly evaporating. The success of this strategy will depend on whether Novo can identify undervalued biotech assets before they are snatched up by deep-pocketed rivals or larger conglomerates looking to enter the metabolic health space.
Explore more exclusive insights at nextfin.ai.
